Survival impact of pelvic and para-aortic lymph node sampling in patients with completely resected stage I-IV uterine serous carcinoma (USC)

2017 ◽  
Vol 145 ◽  
pp. 53-54
Author(s):  
N.M. Acosta ◽  
E.M. Miller ◽  
S. Viswanathan ◽  
V. Hastings ◽  
G.L. Goldberg ◽  
...  
Keyword(s):  
Lymph Node ◽  
Stage I ◽  
Serous Carcinoma ◽  
Lymph Node Sampling ◽  
Aortic Lymph Node ◽  
Uterine Serous Carcinoma ◽  
Resected Stage

Mucoepidermoid variant of adenosquamous carcinoma arising in ovarian dermoid cyst: a case report and review of the literature

2006 ◽  
Vol 16 (Suppl 1) ◽  
pp. 379-384
Author(s):  
A. Karateke ◽  
A. Gurbuz ◽  
G. Kir ◽  
B. Haliloglu ◽  
C. Kabaca ◽  
...  
Keyword(s):  
Case Report ◽  
Lymph Node ◽  
Dermoid Cyst ◽  
Adenosquamous Carcinoma ◽  
Total Abdominal Hysterectomy ◽  
Abdominal Hysterectomy ◽  
Review Of The Literature ◽  
Lymph Node Sampling ◽  
Aortic Lymph Node ◽  
Ovarian Dermoid Cyst

A 40-year-old woman with mucoepidermoid variant of adenosquamous carcinoma arising in dermoid cyst in left ovary is presented. The patient was staged as IC. Total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and pelvic and para-aortic lymph node sampling were carried out. The disease recurred in postoperative 12th month. To our best knowledge, this is 12th case of adenosquamous carcinoma in dermoid cyst and third case of mucoepidermoid variant of adenosquamous carcinoma in the literature.

scholarly journals Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma

2020 ◽  
Vol 156 (1) ◽  
pp. 70-76 ◽  
Author(s):  
Derman Basaran ◽  
Shaina Bruce ◽  
Emeline M. Aviki ◽  
Jennifer J. Mueller ◽  
Vance A. Broach ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Mapping ◽  
Serous Carcinoma ◽  
Lymph Node Mapping ◽  
Extensive Lymphadenectomy ◽  
Uterine Serous Carcinoma

Surgical and Pathological Outcomes of Laparoscopic Versus Abdominal Radical Hysterectomy With Pelvic Lymphadenectomy and/or Para-aortic Lymph Node Sampling for Bulky Early-Stage Cervical Cancer

2017 ◽  
Vol 27 (6) ◽  
pp. 1222-1227 ◽  
Author(s):  
Tao Zhu ◽  
Xi Chen ◽  
Jianqing Zhu ◽  
Yaqing Chen ◽  
Aijun Yu ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Lymph Node ◽  
Radical Hysterectomy ◽  
Early Stage ◽  
Pelvic Lymphadenectomy ◽  
Tumor Diameter ◽  
Laparoscopic Radical Hysterectomy ◽  
Lymph Node Sampling ◽  
Aortic Lymph Node ◽  
Early Stage Cervical Cancer

Background and ObjectivesThe aim of this study was to compare the feasibility, morbidity, and recurrence rate of total laparoscopic radical hysterectomy (LRH) with those of abdominal radical hysterectomy (ARH) for bulky early-stage cervical cancer.MethodsWe performed a retrospective cohort study of 112 patients with stage IB1 or IIA2 cervical cancer in which the tumor diameter was 3 cm or greater. All patients underwent LRH (n = 30) or ARH (n = 82) with pelvic lymphadenectomy and/or para-aortic lymph node sampling between May 2011 and November 2014. Perioperative outcomes were compared between the 2 surgical groups.ResultsThe laparoscopic approach consisted of 4 trocar insertions. Age, tumor diameter, and pelvic lymph nodes significantly differed between the 2 cohorts. Body mass index, International Federation of Gynecology and Obstetrics stage, histologic type and grade, deep stromal invasion, lymphovascular space invasion, positive margins, and adjuvant therapy were not significantly different between the 2 cohorts. Laparoscopic radical hysterectomy exhibited favorable results compared with ARH in terms of operating time, blood loss, intestinal exhaust time, and length of hospital stay. In addition, recurrence was observed in 5 LRH patients (16.7%) and 9 ARH patients (11.7%).ConclusionsThe surgical outcomes of LRH with pelvic lymphadenectomy and/or para-aortic lymph node sampling exhibited a similar therapeutic efficacy to those of the ARH approach.

scholarly journals Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma

2017 ◽  
Vol 147 (1) ◽  
pp. 24-29 ◽  
Author(s):  
Yushen Qian ◽  
Erqi L. Pollom ◽  
Chika Nwachukwu ◽  
Kira Seiger ◽  
Rie von Eyben ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Serous Carcinoma ◽  
Node Metastasis ◽  
Uterine Serous Carcinoma ◽  
Lymphovascular Space Invasion

Population-based treatment and outcomes of Stage I uterine serous carcinoma

2014 ◽  
Vol 132 (1) ◽  
pp. 61-64 ◽  
Author(s):  
Louis J.M. van der Putten ◽  
Paul Hoskins ◽  
Anna Tinker ◽  
Peter Lim ◽  
Christina Aquino-Parsons ◽  
...  
Keyword(s):  
Population Based ◽  
Stage I ◽  
Serous Carcinoma ◽  
Uterine Serous Carcinoma

Single-Port Laparoscopic Pelvic and Para-Aortic Lymph Node Sampling or Lymphadenectomy

2010 ◽  
Vol 20 (7) ◽  
pp. 1268-1273 ◽  
Author(s):  
Pedro F. Escobar ◽  
Amanda Nickles Fader ◽  
Nabila Rasool ◽  
Luis Rojas Espalliat
Keyword(s):  
Lymph Node ◽  
Single Port ◽  
Lymph Node Sampling ◽  
Aortic Lymph Node

scholarly journals Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium

2020 ◽  
Vol 30 (8) ◽  
pp. 1089-1094 ◽  
Author(s):  
Dimitrios Nasioudis ◽  
Allison Grace Roy ◽  
Emily M Ko ◽  
Lori Cory ◽  
Robert L Giuntoli II ◽  
...  
Keyword(s):  
Overall Survival ◽  
Adjuvant Chemotherapy ◽  
Adjuvant Treatment ◽  
Myometrial Invasion ◽  
Stage I ◽  
Serous Carcinoma ◽  
Rank Test ◽  
Survival Difference ◽  
Uterine Serous Carcinoma ◽  
The Impact

ObjectivesThe role of adjuvant treatment for early-stage uterine serous carcinoma is not defined. The goal of this study was to investigate the impact of adjuvant treatment on survival of patients with tumors confined to the endometrium.MethodsPatients diagnosed with stage I uterine serous carcinoma with no myometrial invasion between January 2004 and December 2015 who underwent hysterectomy with at least 10 lymph nodes removed were identified from the National Cancer Database. Adjuvant treatment patterns defined as receipt of chemotherapy and/or radiotherapy within 6 months from surgery were investigated and overall survival was evaluated using Kaplan–Meier curves, and compared with the log-rank test for patients with at least one month of follow-up. A Cox analysis was performed to control for confounders.ResultsA total of 1709 patients were identified; 833 (48.7%) did not receive adjuvant treatment, 348 (20.4%) received both chemotherapy and radiotherapy, 353 (20.7%) received chemotherapy only, and 175 (10.2%) received radiotherapy only. Five-year overall survival rates for patients who did not receive adjuvant treatment (n=736) was 81.9%, compared with 91.3% for those who had chemoradiation (n=293), 85.1% for those who received radiotherapy only (n=143), and 91.0% for those who received chemotherapy only (n=298) (p<0.001). After controlling for age, insurance status, type of treatment facility, tumor size, co-morbidities, and history of another tumor, patients who received adjuvant chemotherapy (HR 0.64, 95% CI 0.42, 0.96), or chemoradiation (HR 0.55, 95% CI 0.35, 0.88) had better survival compared with those who did not receive any adjuvant treatment, while there was no benefit from radiotherapy alone (HR 0.85, 95% CI 0.53, 1.37). There was no survival difference between chemoradiation and chemotherapy only (HR 1.15, 95% CI 0.65, 2.01).ConclusionAdjuvant chemotherapy (with or without radiotherapy) is associated with a survival benefit for uterine serous carcinoma confined to the endometrium.

Sign in / Sign up

Export Citation Format

Share Document